IBD occurred in 132 patients: 72 new IL-17 inhibitor users (0.43%), 11 new apremilast users (0.05%) and 49 new etanercept users (0.48%). Most IBD cases occurred after six months of exposure (82%, 55% and 76%, respectively). After propensity score weighting, the risk of IBD was significantly greater among patients initiating an IL-17 inhibitor than among those initiating apremilast (weighted hazard ratio [HR] 3.8 [95% confidence interval (95% CI) 2.1–6.8]). No difference in the risk of IBD between new IL-17 inhibitor users and new etanercept users was observed (weighted HR 0.8 [95% CI 0.5–1.2]).
Conclusion
Although the results need to be confirmed in other large studies, the researchers found that patients with psoriasis and PsA/AS treated with an IL-17 inhibitor do not have a higher risk of developing IBD than patients with the same severity of underlying disease treated with etanercept.
For full study details, including source material, refer to the full article.
Excerpted and adapted from:
Penso L, Bergqvist C, Meyer A, et al. Risk of inflammatory bowel disease in patients with psoriasis and psoriatic arthritis/ankylosing spondylitis initiating interleukin-17 inhibitors: A nationwide population-based study using the French national health data system. Arthritis Rheumatol. 2022 Feb;74(2): 244–252.
